NCT05193591View on ClinicalTrials.gov

Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

September 10, 2025

Study Completion Date

September 10, 2025

Conditions
Lupus Erythematosus, Systemic
Interventions
OTHER

Autoantibodies evaluation in lupus

"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."

Trial Locations (2)

13005

RECRUITING

AP-HM_Hôpital de la Conception, Marseille

38043

RECRUITING

CHU Grenoble Alpes, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

collaborator

University Hospital, Marseille

OTHER

NCT05193591 - Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322) | Biotech Hunter | Biotech Hunter